FAP-Targeting Ligand Chelation for Stable Tumor Radiolabeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing effective fibroblast activation protein (FAP)-binding agents with favorable tumor-to-organ biodistribution, high activity labeling, and good compound stability remains challenging for targeted small molecule drug conjugates and radioconjugates.
Innovation Solution
A ligand for FAP is developed, represented by formula (I) or its pharmaceutically acceptable salts, which includes specific functional groups for optical imaging, PET, or radiation therapy, and can be labeled with radioactive elements for targeted delivery to disease sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional FAP-binding agents are used, then some level of target binding is achieved, but favorable tumor-to-organ biodistribution, high activity labeling, and good compound stability cannot be simultaneously achieved
Solution Approach 1:
The molecule is divided into distinct functional modules: a FAP-targeting ligand portion (containing quinoline or isoquinoline core with specific substituents) and a chelating agent portion (such as DOTA or NOTA). This segmentation allows each module to be optimized independently for its specific function while maintaining overall molecular stability and targeting efficiency.
Solution Approach 2:
The invention creates a composite molecular structure by covalently linking a FAP-binding ligand (small molecule organic compound with specific heterocyclic core) to a chelating agent (macrocyclic polyaminopolycarboxylic acid). This composite structure combines the target-specific binding properties of the ligand with the stable metal coordination properties of the chelator, achieving both favorable biodistribution and compound stability.
2Measurement precision
If small molecule radioconjugates are developed for FAP targeting, then targeted delivery capability is improved, but achieving high activity labeling and favorable tumor-to-organ biodistribution simultaneously remains challenging
Solution Approach 1:
The chelating agent is pre-installed on the FAP-targeting ligand during organic synthesis, creating a pre-assembled conjugate ready for radioactive labeling. This preliminary action eliminates the need for complex in situ labeling procedures and enables straightforward, high-yield radiolabeling under mild conditions, improving both targeting precision and ease of manufacture.
Solution Approach 2:
The chelating agent acts as an intermediary component that bridges the FAP-targeting ligand and the radioactive metal ion. This intermediary structure facilitates efficient and stable coordination of the radionuclide while maintaining the integrity and targeting capability of the original ligand, thereby achieving high activity labeling with favorable biodistribution.
3Productivity
If FAP-targeted radioconjugates are designed, then tumor targeting capability is enhanced, but good compound stability and high activity labeling are difficult to achieve together
Solution Approach 1:
The invention optimizes the chemical parameters of the chelating agent (such as macrocycle ring size, number of coordinating atoms, and substituent patterns) to achieve optimal stability constants for radionuclide complexation. By carefully adjusting these parameters, the system achieves both high labeling efficiency under mild conditions and exceptional stability of the resulting radioconjugate in biological environments.
Solution Approach 2:
The chelating agent is designed with specific local chemical properties (macrocyclic structure with multiple coordinating groups positioned in specific spatial arrangements) that create a highly stable coordination environment for the radioactive metal ion. This localized optimization of chemical properties at the metal-binding site ensures both efficient labeling and long-term stability without affecting the overall targeting function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ligand effectively delivers a radioactive payload to FAP-expressing tissues, enabling imaging and therapeutic interventions with improved tumor-to-organ biodistribution and stability.
Implementation Method 1
B is composed of a chelating agent and a radioactive element
Data Source
AI summary
The present disclosure relates to a ligand targeting a fibroblast activation protein, and particularly to a ligand represented by formula (I) and targeting a fibroblast activation protein, and a radioactive label thereof, wherein each substituent is defined in the description. The ligand can be used for imaging diseases or disorders related to the fibroblast activation protein, or treating the diseases or disorders related to the fibroblast activation protein.